PCM
CRSP icon

Poehling Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Poehling Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10
Closed -$1K – 143
2018
Q2 		$1K Buy
+10
New +$570 ﹤0.01% 282

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Poehling Capital Management's CRSP Position: Q3 2018 in Review

Poehling Capital Management sold out of CRISPR Therapeutics (CRSP) in Q3 2018, closing a stake of 10 shares — an estimated $1K sold.

Poehling Capital Management first reported a position in CRSP in Q2 2018 and held it in 1 quarter. The position peaked at $1K in Q2 2018. 179 funds tracked by Wall St. Rank hold CRSP as of Q3 2018.

  • Poehling Capital Management reported no remaining CRISPR Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Poehling Capital Management sold 10 CRISPR Therapeutics shares in Q3 2018, an estimated $1K.
  • Poehling Capital Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 1 quarter.
  • Poehling Capital Management's CRISPR Therapeutics position peaked at $1K in Q2 2018.
  • 179 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2018.

Based on Poehling Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.